Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• The PARADIGM-HF trial demonstrated that LCZ696 (an angiotensin-receptor-neprilysin inhibitor) reduced cardiovascular and all-cause mortality in chronic heart failure patients compared to enalapril.
• Understanding the specific components of this mortality benefit is crucial for optimizing heart failure management.

Purpose of the Study:

• To analyze the effect of LCZ696 on the mode of death in patients with chronic heart failure.
• To elucidate the specific cardiovascular death categories impacted by LCZ696 treatment.

Main Methods:

• Prospective, double-blind, randomized trial (PARADIGM-HF) involving 8399 patients with chronic heart failure (NYHA Class II-IV, LVEF ≤40%).
• Patients received guideline-recommended therapy and were followed for a median of 27 months.
• Mode of death was adjudicated by a blinded clinical endpoints committee.

Main Results:

• The majority of deaths (80.9%) were cardiovascular.
• LCZ696 significantly reduced the risk of overall cardiovascular death (HR 0.80, P < 0.001).
• Treatment with LCZ696 led to significant reductions in both sudden cardiac death (HR 0.80, P = 0.008) and death due to worsening heart failure (HR 0.79, P = 0.034).
• Non-cardiovascular deaths and deaths from other cardiovascular causes (myocardial infarction, stroke) were infrequent and evenly distributed.

Conclusions:

• LCZ696 demonstrated superiority over enalapril in reducing cardiovascular mortality in chronic heart failure.
• The mortality benefit of LCZ696 is attributed to significant reductions in both sudden cardiac death and death from progressive heart failure.